General
Preferred name
nemiralisib
Synonyms
GSK2269557 ()
GSK-2269557 ()
GSK2269557 (free base) ()
GSK-2269557 FREE BASE ()
GSK-2269557A ()
GSK2269557A ()
Nemiralisib succinate ()
Nemiralisib hydrochloride ()
GSK-2269557H ()
Nemiralisib hemisuccinate ()
GSK2269557H ()
P&D ID
PD053924
CAS
1254036-71-9
1254036-77-5
Tags
available
drug candidate
Drug indication
Chronic obstructive pulmonary disease
Asthma
Drug Status
investigational
Max Phase
2.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Nemiralisib (GSK2269557) is a PI3K inhibitor with selectivity for PI3Kδ over the other related isoforms . The compound is active via inhalation and is being evaluated for its potential in respiratory inflammation. May be administered or used experimentally as the hydrochloride salt (PubChem CID 49784084). In the original study by Down et al. (2015) compound 3 () was developed as a follow-up compound with reduced hERG activity and minimised systemic exposure .
(GtoPdb)
DESCRIPTION
Nemiralisib (GSK2269557 free base) is a potent and highly selective PI3K¦Ä inhibitor with a pKi of 9.9.
PRICE
133
DESCRIPTION
Nemiralisib(GSK-2269557 free base) is an orally available, potent and specific PI3K?? inhibitor with a pKi of 9.9.Nemiralisib is used for the treatment of respiratory diseases including chronic obstructive pulmonary disease.
DESCRIPTION
GSK2269557, an effective PI3K inhibitor, could be used as against inflammatory and some autoimmune diseases. It has just completes a phase II trial against Asthma.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Nemiralisib(GSK-2269557 free base) is an orally available, potent and specific PI3Kδ inhibitor with a pKi of 9.9.Nemiralisib is used for the treatment of respiratory diseases including chronic obstructive pulmonary disease.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
16
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Kinase Chemogenomic Set (KCGS)
MedChem Express Bioactive Compound Library
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
37
Molecular Weight
440.23
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
6
Aromatic Ring Count
5
cLogP
4.89
TPSA
76.98
Fraction CSP3
0.31
Chiral centers
0.0
Largest ring
6.0
QED
0.41
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
PI3Kδ
PIK3CD
PI3K
Pathway
PI3K/Akt/mTOR signaling
PI3K/Akt/mTOR
Solubility
DMSO
Recommended Cell Concentration
None
Source data
